Fairfield, Bush & Co. Amgen Inc Transaction History

Fairfield, Bush & Co.

  • $168 Billion
  • Q3 2024

A detailed history of Fairfield, Bush & Co. transactions in Amgen Inc stock. As of the latest transaction made, Fairfield, Bush & Co. holds 3,267 shares of AMGN stock, worth $962,229. This represents 0.63% of its overall portfolio holdings.

Number of Shares
3,267
Previous 3,355 2.62%
Holding current value
$962,229
Previous $1.05 Billion 0.42%
% of portfolio
0.63%
Previous 0.63%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$309.38 - $337.38 $27,225 - $29,689
-88 Reduced 2.62%
3,267 $1.05 Billion
Q2 2024

Aug 15, 2024
BUY
$262.75 - $319.31 $116,398 - $141,454
443 Added 15.21%
3,355 $1.05 Billion
Q1 2024

May 15, 2024
SELL
$268.87 - $324.56 $45,439 - $54,850
-169 Reduced 5.49%
2,912 $828 Million
Q4 2023

Feb 13, 2024
BUY
$255.7 - $288.46 $69,806 - $78,749
273 Added 9.72%
3,081 $887 Million
Q3 2023

Nov 15, 2023
SELL
$218.65 - $271.46 $4.68 Million - $5.82 Million
-21,422 Reduced 88.41%
2,808 $755 Million
Q2 2023

Aug 15, 2023
BUY
$214.27 - $253.37 $424,683 - $502,179
1,982 Added 8.91%
24,230 $5.38 Billion
Q1 2023

May 15, 2023
BUY
$225.79 - $275.2 $4.6 Million - $5.6 Million
20,367 Added 1082.78%
22,248 $5.38 Billion
Q4 2022

Feb 14, 2023
SELL
$229.03 - $291.01 $111,995 - $142,303
-489 Reduced 20.63%
1,881 $494 Million
Q3 2022

Nov 07, 2022
SELL
$224.46 - $253.15 $22,446 - $25,315
-100 Reduced 4.05%
2,370 $534,000
Q2 2022

Aug 09, 2022
SELL
$230.71 - $256.74 $128,044 - $142,490
-555 Reduced 18.35%
2,470 $601,000
Q1 2022

May 06, 2022
SELL
$219.27 - $242.57 $87,708 - $97,028
-400 Reduced 11.68%
3,025 $732,000
Q4 2021

Feb 09, 2022
SELL
$198.88 - $227.6 $1.56 Million - $1.78 Million
-7,840 Reduced 69.6%
3,425 $771,000
Q3 2021

Nov 08, 2021
SELL
$212.27 - $248.7 $2.7 Million - $3.16 Million
-12,720 Reduced 53.03%
11,265 $2.4 Million
Q2 2021

Aug 02, 2021
BUY
$233.58 - $259.14 $291,975 - $323,925
1,250 Added 5.5%
23,985 $5.85 Million
Q1 2021

May 14, 2021
SELL
$221.91 - $258.6 $99,859 - $116,370
-450 Reduced 1.94%
22,735 $5.66 Million
Q4 2020

Feb 12, 2021
SELL
$216.38 - $257.67 $45,439 - $54,110
-210 Reduced 0.9%
23,185 $5.33 Million
Q3 2020

Nov 18, 2020
SELL
$234.65 - $260.95 $206,492 - $229,636
-880 Reduced 3.63%
23,395 $5.95 Million
Q2 2020

Aug 13, 2020
BUY
$197.81 - $242.74 $23,935 - $29,371
121 Added 0.5%
24,275 $5.73 Million
Q1 2020

May 13, 2020
BUY
$182.24 - $241.7 $48,293 - $64,050
265 Added 1.11%
24,154 $4.9 Million
Q4 2019

Feb 12, 2020
SELL
$189.21 - $243.2 $94,605 - $121,600
-500 Reduced 2.05%
23,889 $5.76 Million
Q3 2019

Nov 13, 2019
SELL
$174.11 - $208.62 $67,554 - $80,944
-388 Reduced 1.57%
24,389 $4.72 Million
Q2 2019

Aug 13, 2019
BUY
$166.7 - $195.41 $16,670 - $19,541
100 Added 0.41%
24,777 $4.57 Million
Q1 2019

May 15, 2019
SELL
$180.87 - $203.88 $1.49 Million - $1.68 Million
-8,255 Reduced 25.07%
24,677 $5.65 Million
Q4 2018

Feb 11, 2019
SELL
$178.4 - $208.25 $89,556 - $104,541
-502 Reduced 1.5%
32,932 $6.41 Million
Q3 2018

Nov 13, 2018
SELL
$185.29 - $208.89 $92,645 - $104,445
-500 Reduced 1.47%
33,434 $6.93 Million
Q2 2018

Aug 16, 2018
BUY
$166.05 - $186.51 $43,173 - $48,492
260 Added 0.77%
33,934 $6.26 Million
Q1 2018

May 09, 2018
SELL
$169.43 - $198.0 $116,398 - $136,026
-687 Reduced 2.0%
33,674 $5.74 Million
Q4 2017

Feb 22, 2018
BUY
$168.79 - $188.59 $205,079 - $229,136
1,215 Added 3.67%
34,361 $5.98 Million
Q3 2017

Nov 14, 2017
SELL
$167.29 - $191.0 $33,458 - $38,200
-200 Reduced 0.6%
33,146 $6.18 Million
Q2 2017

Aug 15, 2017
BUY
N/A
33,346
33,346 $5.74 Million

Others Institutions Holding AMGN

# of Institutions
3,122
Shares Held
410M
Call Options Held
7.56M
Put Options Held
7.2M
View Full List

About AMGEN INC

AMGN Quotes by TradingView
  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $158B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Fairfield, Bush & Co. Portfolio

Follow Fairfield, Bush & Co. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fairfield, Bush & Co., based on Form 13F filings with the SEC.

News

Stay updated on Fairfield, Bush & Co. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email